Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.62 |
| ▸ | PARP2 | Q9UGN5 | 15/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 15/20 | 0.56 |
| ▸ | TNKS | O95271 | 2/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.55 |
| ▸ | PARP16 | Q8N5Y8 | 2/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.55 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719630 | 0.95 | PARP1 (0.64) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14718536 | 0.94 | PARP1 (0.62) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14719166 | 0.90 | PARP1 (0.67) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14719313 | 0.90 | PARP1 (0.64) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14719018 | 0.89 | PARP1 (0.54) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14718581 | 0.89 | PARP1 (0.56) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14718576 | 0.89 | PARP1 (0.66) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14719385 | 0.88 | PARP1 (0.51) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14718941 | 0.86 | PARP1 (0.62) | PARP1PARP2PARP3TNKSPARP10 | |
| SCHEMBL14718805 | 0.86 | PARP1 (0.57) | PARP1PARP2PARP3TNKSPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | claimed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053365-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.